Nov. 12, 2024 — Enspectra Health recently announced the publication of its cross-modal imaging technology, a method for real-time visualization of skin cellular structure and composition, in Scientific Reports, a journal of the Nature Research family. The publication, titled "Handheld multiphoton and pinhole-free reflectance confocal microscopy enables noninvasive real-time, cross-sectional imaging of skin," was published online. Easily portable and handheld, cross-model imaging digitizes histopathology directly from a patient's skin to provide actionable health insights for dermatologists.
"Our aim is to make the invisible digital by unveiling cellular and molecular information beneath the skin's surface," said Gabriel Sanchez, Ph.D., CEO and co-founder of Enspectra Health. "We believe cross-modal imaging is a patient-centric platform that will usher in a new era of digital dermatology."
The scientific publication outlines how cross-modal technology overcomes the limitations of prior imaging modalities such as monochromatic images and rigid positioning of patients. The cross-modal imaging technology delivers high-resolution, multi-color (Tetrachrom) results in an intuitive, user-friendly system making it a practical solution for in-office dermatology practices. The technology was evaluated with healthy human participants ranging in age from 9–81 years and in skin type diversity from Fitzpatrick I-V. Ethnic representation was a strength of the study; 43% of participants identified as Hispanic/Latino, Asian, Black/African American, or as multiracial. Additionally, feasibility performance was evaluated in lesions suspected of skin cancer with observational results consistent with traditional H&E histopathology.
"Enspectra Health's cross-modal technology is a very exciting innovation that can transform how skin is assessed in dermatology," said Roberto Novoa, MD, board-certified dermatologist and dermatopathologist. "I can envision a future where physicians integrate noninvasive cross-modal imaging into their workflow in order to have instantly available clinical insights enabling them to provide personalized patient care."
Enspectra Health is redefining how skin health is managed by leveraging artificial intelligence to build applications from cross-modal imaging data. The generated datasets unlock rich morphological and compositional data which, when coupled with machine learning, can drive advances in clinical decision support and predictive modeling.
"The skin is a window into human health and Enspectra Health's innovation allows us a look into that window," said Justin Ko, MD, MBA board-certified dermatologist. "The ability to create digital datasets of diverse skin types enables the meaningful application of A.I. in dermatology."
For more information, please visit www.enspectrahealth.com.
February 24, 2026 
